GSK Plays Up Avandia As Diabetes “Engine” After DPP-4 Program Stalls
GlaxoSmithKline does not believe development of its own dipeptidyl peptidase-4 inhibitor is integral to growing the firm's diabetes franchise
GlaxoSmithKline does not believe development of its own dipeptidyl peptidase-4 inhibitor is integral to growing the firm's diabetes franchise